Literature DB >> 15137508

Analysis of effective molecular diffusion rates for verteporfin in subcutaneous versus orthotopic Dunning prostate tumors.

Xiaodong Zhou1, Brian W Pogue, Bin Chen, Tayyaba Hasan.   

Abstract

Photosensitizer biodistribution change inside tissue is one of the dominant factors in photodynamic therapy efficacy. In this study, the pharmacokinetics of a benzoporphyrin derivative (BPD), delivered in verteporfin for injection formulation, have been quantified in the rat Dunning prostate tumor MAT-LyLu model, using both subcutaneous and orthotopic sites. Blood plasma sampling indicated that BPD had a bi-exponential metabolic lifetime in vivo, with the two lifetimes being 9.6 min and 8.3 h. The spatial distributions in the tumor were quantified as a function of distance from the perfused blood vessels, using fluorescence histologic images of the tumor. A fluorescent vascular marker was used to obtain locations and shapes of perfused capillaries at a wavelength of emission different from that of BPD and to allow colocalized images to be acquired of vessel and BPD locations. Using the BPD fluorescence images obtained 15 min after intravenous administration, a forward finite-element solution to the diffusion equation was used to predict the drug distribution by matching the fluorescence intensity images observed microscopically. An inverse solver was used to minimize the root mean square error between the image of simulated diffusion and the experimental image, resulting in estimation of the diffusion coefficient of BPD in the tumor models. Effective diffusion coefficients were 0.88 and 1.59 microm2/s for the subcutaneous and orthotopically grown tumors, respectively, indicating that orthotopic tumors have significantly higher vascular extravasation rates as compared with subcutaneous tumors. This analysis supports the hypothesis that leakage rates of the photosensitizer vary considerably. Thus, although varying the time between injection and optical irradiation may be used to vary the targeting between vascular and less vascular areas, the precise time of treatment will depend on the nature of the permeability of the vasculature in the tissue being treated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15137508     DOI: 10.1562/MU-03-31.1

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.421


  9 in total

1.  Tumor vascular microenvironment determines responsiveness to photodynamic therapy.

Authors:  Amanda L Maas; Shirron L Carter; E Paul Wileyto; Joann Miller; Min Yuan; Guoqiang Yu; Amy C Durham; Theresa M Busch
Journal:  Cancer Res       Date:  2012-02-28       Impact factor: 12.701

2.  Contrast enhanced-magnetic resonance imaging as a surrogate to map verteporfin delivery in photodynamic therapy.

Authors:  Kimberley S Samkoe; Amber Bryant; Jason R Gunn; Stephen P Pereira; Tayyaba Hasan; Brian W Pogue
Journal:  J Biomed Opt       Date:  2013-12       Impact factor: 3.170

3.  3-D photoacoustic and pulse echo imaging of prostate tumor progression in the mouse window chamber.

Authors:  Daniel R Bauer; Ragnar Olafsson; Leonardo G Montilla; Russell S Witte
Journal:  J Biomed Opt       Date:  2011-02       Impact factor: 3.170

4.  Mechanisms in photodynamic therapy: Part three-Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction.

Authors:  Ana P Castano; Tatiana N Demidova; Michael R Hamblin
Journal:  Photodiagnosis Photodyn Ther       Date:  2005-08-10       Impact factor: 3.631

5.  Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.

Authors:  Anne Marie Barrette; Halle Ronk; Tanvi Joshi; Zarmeen Mussa; Meenakshi Mehrotra; Alexandros Bouras; German Nudelman; Joe Gerald Jesu Raj; Dominique Bozec; William Lam; Jane Houldsworth; Raymund Yong; Elena Zaslavsky; Constantinos G Hadjipanayis; Marc R Birtwistle; Nadejda M Tsankova
Journal:  Neuro Oncol       Date:  2022-05-04       Impact factor: 13.029

6.  In vivo confocal fluorescence imaging of the intratumor distribution of the photosensitizer mono-L-aspartylchlorin-e6.

Authors:  Soumya Mitra; Thomas H Foster
Journal:  Neoplasia       Date:  2008-05       Impact factor: 5.715

7.  Protoporphyrin IX fluorescence photobleaching increases with the use of fractionated irradiation in the esophagus.

Authors:  Brian W Pogue; Chao Sheng; Juan Benevides; David Forcione; Bill Puricelli; Norm Nishioka; Tayyaba Hasan
Journal:  J Biomed Opt       Date:  2008 May-Jun       Impact factor: 3.170

8.  Quantitative imaging of scattering changes associated with epithelial proliferation, necrosis, and fibrosis in tumors using microsampling reflectance spectroscopy.

Authors:  Venkataramanan Krishnaswamy; P Jack Hoopes; Kimberley S Samkoe; Julia A O'Hara; Tayyaba Hasan; Brian W Pogue
Journal:  J Biomed Opt       Date:  2009 Jan-Feb       Impact factor: 3.170

9.  Reactive oxygen species explicit dosimetry to predict tumor growth for benzoporphyrin derivative-mediated vascular photodynamic therapy.

Authors:  Tianqi Sheng; Yi Hong Ong; Wensheng Guo; Timothy Zhu
Journal:  J Biomed Opt       Date:  2020-01       Impact factor: 3.170

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.